Healthcare's financial incentives are broken — and most people have no idea. We're pulling back the curtain on who gets paid for what, why your premiums keep rising, and the forces conspiring to keep it that way.
Every year, employers and individuals pay more for healthcare — and get less in return. The reasons aren't mysterious. They're structural, financial, and deliberately obscured by the parties that benefit from the confusion.
Healthcare is a business. We break down the financial relationships between insurers, hospitals, drug companies, and middlemen — and what they mean for what you pay.
Premiums go up every year. Deductibles go up every year. We explain the underlying economic forces — and who profits from the cycle.
Diagnostics guide 70%+ of clinical decisions but represent less than 5% of healthcare spending. The result: treatments administered without the information needed to know if they'll work.
Pharmacy Benefit Managers were supposed to lower drug costs. Instead, they've become one of the most powerful — and least understood — forces driving them up. We explain how.
through insurance premiums, pharmacy benefit managers, drug pricing, diagnostic gaps, and the incentive structures that keep costs rising no matter what anyone does. No jargon. No agenda. Just honest answers to the questions you're asking.
Whether you're managing a benefits budget, navigating coverage decisions, or just trying to understand why your EOB looks the way it does — Dirty Little Secrets was made for you.
You're signing off on a healthcare spend that keeps growing with limited visibility into why. We give you the economic literacy to ask better questions — of your carriers, your PBMs, and your benefits consultants.
The people making coverage decisions deserve to understand the full picture of the financial incentives shaping the market — including the ones working against their members' interests.
You don't need to be in healthcare to want to understand it. If you've ever been surprised by a bill, denied a claim, or wondered why a drug costs what it costs — this show is for you.

Hannah Mamuszka and Lena Chaihorsky interview entrepreneur Mark Cuban about why U.S. drug and healthcare prices are so high — and what he’s building to counter them. Cuban walks through the drug supply chain: brand manufacturers sell to three dominant distributors, then pharmacy benefit managers (PBMs) — the three largest of which are owned by […]

Hannah Mamuszka and Lena Chaihorsky interview Greg Baker, founder and CEO of AffirmedRx, a pharmacy benefit manager structured as a public benefit corporation. Baker, a pharmacist who spent years running on-site pharmacies for large employers, argues the drug-pricing system isn’t broken but “working as designed” to maximize shareholder profit. He explains how the dominant PBMs […]

Hannah Mamuszka and Lena Chaihorsky take on the drug pricing debate from the patient’s side, where the question is not what a drug costs but whether it works for the person taking it. Chaihorsky frames it with a metaphor that runs through the episode: we argue endlessly over the price of milk while ignoring that […]

Hannah Mamuszka and Lena Chaihorsky interview Kristine Ashcraft, a molecular biologist who has worked in pharmacogenomics since 2000 — first at Genelex, one of the earliest labs to offer the testing, and later as founder of the clinical-decision-support tool YouScript. Ashcraft traces the field’s slow adoption despite strong evidence. She explains that the vast majority […]
Hannah founded Alva10 after spending two decades watching technically excellent diagnostics fail to reach patients — not because of bad science, but because of misaligned financial incentives. She has worked on the lab side, the business side, and the payer side of healthcare, giving her a full-system view of where the money flows and why. A frequent writer and speaker on healthcare economics, Hannah brings the rare ability to translate both the science behind the curtain and the financial architecture of healthcare into something anyone can understand — and get appropriately angry about.
Lena is a nationally recognized expert on precision medicine in the employer space — translating its clinical and financial implications for the benefits leaders who decide how employers invest in their workforce's health. She has spent her career designing the economic cases that move healthcare innovation from promising to covered. As the leader of the National Association of Brokers' precision medicine certification effort, Lena works daily at the intersection of what the system could be and what it currently is — and she has plenty to say about the gap between the two.